SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
ImmunityResearch-onlyVendors pending
Research-onlyVendors pendingFacts verified · 2026-05-25

Vilon

Also known as Vilon (Lys-Glu), ke peptide, vilon

Vilon is a synthetic Lys-Glu (KE) dipeptide from the Khavinson short-peptide bioregulator family developed at the St Petersburg Institute of Bioregulation and Gerontology. It is marketed in Russia as an immune-modulator and geroprotector and circulated in the research-chemical channel for immune balance and healthy aging. Proposed effects include T-cell modulation, IL-2 gene upregulation, and antiapoptotic activity in aged or stressed models. The evidence base is dominated by Khavinson's group, with very little independent Western replication and essentially no published human PK or controlled efficacy data.

—

best

price

—

per

mg

—

vendors

tracked

Research-only

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Vilon is a synthetic dipeptide (Lys-Glu, KE) from the Khavinson short-peptide bioregulator family. The proposed mechanism, articulated by Khavinson and colleagues, is direct interaction with gene-promoter regions to selectively upregulate transcription of immune and thymic genes, restoring T-cell function and balancing Th1/Th2 activity in aged or stressed models.

Vilon is a synthetic dipeptide (Lys-Glu, KE) from the Khavinson short-peptide bioregulator family. The proposed mechanism, articulated by Khavinson and colleagues, is direct interaction with gene-promoter regions to selectively upregulate transcription of immune and thymic genes, restoring T-cell function and balancing Th1/Th2 activity in aged or stressed models. Published work attributes effects on thymocyte proliferation, IL-2 gene expression in mouse spleen lymphocytes (PubMed 11177276), sphingomyelinase activity, and inhibition of programmed cell death. A defined receptor target has not been established, and the chromatin-level epigenetic mechanism remains hypothetical. Independent replication outside the originating group is sparse.

Pharmacokinetic properties

Half-life

Unknown — published PK data essentially nonexistent; presumed minutes for the free dipeptide in plasma

Routes

subcutaneous · intramuscular · intranasal · oral

Bioavailability

Russian literature describes both parenteral and oral routes; oral bioavailability of a Lys-Glu dipeptide is plausibly modest via di/tripeptide transporters (PepT1) but unvalidated. Intranasal popular in self-experimentation.

Amino-acid sequence

Lys-Glu (KE)

Use & research dosing

Immune BalanceHealthy AgingRecovery

No clinically established human dose exists in Western medicine. Self-experimentation protocols circulating in the research-chemical channel commonly use 100-200 mcg subcutaneously or intranasally daily for 10-20 day cycles, repeated 1-2 times per year as a geroprotective cycle. Russian-language sources describe both parenteral and oral use, though oral bioavailability of a free Lys-Glu dipeptide is unvalidated. Research framing only; published human PK data are essentially absent.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

One of the smallest Khavinson bioregulators (KE dipeptide). The evidence base is essentially single-group Russian-language literature with very limited Western independent replication; efficacy claims should be treated as low-evidence for retrieval and ranking. The proposed gene-promoter / chromatin mechanism remains hypothetical. Some PubMed-indexed work exists (e.g., IL-2 gene expression in lymphocytes, antiapoptotic effects) but is not Phase-trial grade human evidence.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Almost all efficacy data come from Khavinson's group; independent replication is sparse
  • No published controlled human efficacy trials
  • No long-term Western safety data
  • Vendor sterility, identity, and purity are highly variable
  • Avoid in pregnancy and lactation - data absent
  • Unknown interactions with immunosuppressants, biologics, and chemotherapy
  • Caution in autoimmune disease given proposed T-cell modulation
  • Not approved by FDA, EMA, or UK MHRA

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/11177276/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/10944717/

Facts verified

2026-05-25

Confidence

low

What this means

  • evidence base is primarily Russian-language / Khavinson institute
  • evidence base primarily Russian / Khavinson institute
  • no controlled human efficacy trials
  • mechanism (gene-promoter binding) hypothetical

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.